News

Reviva Pharmaceuticals has been awarded a U.S. patent covering the use of its experimental therapy brilaroxazine in treating people with pulmonary fibrosis. The patent, No. 12053477, granted by the U.S. Patent and Trademark Office specifically covers the use of brilaroxazine in idiopathic pulmonary fibrosis (IPF), as well…

Brainomix, a U.K.-based software company, has joined forces with Boehringer Ingelheim, a German pharmaceutical company, to accelerate the diagnosis of pulmonary fibrosis (PF) in the U.S. and improve treatment access for people with scarring of the lungs. As part of the collaboration, Brainomix’s artificial intelligence (AI)-powered tool, called Brainomix 360…

Enrollment has been completed for a Phase 2a study that’s testing idiopathic pulmonary fibrosis (IPF) treatment BBT-877, an investigational therapy from Bridge Biotherapeutics. The Phase 2a trial (NCT05483907) is evaluating the safety, tolerability, and efficacy of BBT-877 in 120 adults with IPF, ages 40 and older, with or…

Enrollment is complete for a Phase 3 clinical trial testing Tyvaso (treprostinil) inhalation solution for idiopathic pulmonary fibrosis (IPF), United Therapeutics, the therapy’s developer, said. The TETON 2 study (NCT05255991) will evaluate the treatment’s safety and efficacy in 597 adults with IPF, 40 years and older,…

An interdisciplinary group of researchers at the University of Wisconsin (UW)-Madison have received nearly $11 million to study the biological processes that promote lung scarring in idiopathic pulmonary fibrosis (IPF). Funding comes from a four-year grant (HT94252410543) provided by the U.S. Department of Defense. The research will be…

A Phase 2a clinical trial testing the safety of treatment candidate INS018_055 among idiopathic pulmonary fibrosis (IPF) patients in the U.S. is still seeking participants, while a parallel trial in China has now completed enrollment. That’s according to an update from Insilico Medicine, which developed the oral therapy with…

Imaging with a tracer that homes in on scar-forming fibroblasts may help predict the progression of pulmonary fibrosis in people with interstitial lung disease (ILD), offering doctors a way to gauge who should be monitored more closely or begin preventive treatment. That tracer, a radiolabeled form of the fibroblast…

AGMB-447, an inhaled treatment for idiopathic pulmonary fibrosis (IPF) now being tested in a Phase 1 clinical trial, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA). The FDA gives this designation to therapies that may improve care for people with rare diseases,…

The U.S. Food and Drug Administration (FDA) has granted its orphan drug designation to Alentis Therapeutics’ antibody-based therapy lixudebart (ALE.F02) for idiopathic pulmonary fibrosis (IPF). Orphan drug designation is given to support the accelerated development of investigational treatments for rare diseases, defined as those affecting fewer than 200,000…

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The results, which also showed the treatment had an acceptable tolerability profile, were presented in a late-breaking oral…